Covid-19 and low molecular weight heparin therapy: retrospective study of 257 patients.

Marco Stabile (marcostabile@gmail.com)
Castel San Giovanni Hospital, ASL PC, Italy  https://orcid.org/0000-0001-6168-2605

Daniela Aschieri
Castel San Giovanni Hospital, ASL PC, Italy

Cristina Maestri
Castel San Giovanni Hospital, ASL PC, Italy

Luca Rosato
Castel San Giovanni Hospital, ASL PC, Italy

Paola Novara
Castel San Giovanni Hospital, ASL PC, Italy

Gianluca Lanati
Castel San Giovanni Hospital, ASL PC, Italy

Mariateresa Di Dio
Castel San Giovanni Hospital, ASL PC, Italy

Cosimo Franco
Castel San Giovanni Hospital, ASL PC, Italy

Giuseppina Bisceglie
Castel San Giovanni Hospital, ASL PC, Italy

Giuseppe Leddi
Castel San Giovanni Hospital, ASL PC, Italy

Enrico fabrizi
Catholic University Piacenza, Italy

Paola Rucci
Alma Mater Studiorum University, Bologna, Italy

Gloria Taliani
Sapienza University Roma, Italy

Short Report

Keywords: COVID-19, Heparin, Pneumonia, Thrombosis, Antithrombotic Therapy, Mortality

DOI: https://doi.org/10.21203/rs.3.rs-57730/v1
Abstract

Objective To evaluate the role of low molecular weight heparin in COVID-19 treatment.

Design Retrospective cohort study

Setting Patients with COVID-19 pneumonia consecutively admitted to Castel San Giovanni COVID-Hospital from February 29, to April 7, 2020.

Main outcome measure Hospital mortality and safety in patients treated with low molecular weight heparin.

Results Of the 257 patients enrolled, 49 (19.1%) died during the hospitalization. Hospital mortality was significantly lower in patients treated with therapeutic dose of low molecular weight heparin (T-LMWH) (17/126, 13.5%), compared with patients treated with prophylactic dose (P-LMWH) (32/131, 24.4%; \( \chi^2 = 4.98, p = 0.02 \)). Crude and adjusted odds ratios of mortality for patients treated with T-LMWH were OR=0.483, 95% CI 0.252-0.923 and OR=0.374, 95% CI 0.177-0.792. In a stratified analysis by ventilation type, the only subgroup of patients who benefited from therapeutic doses of heparin were those receiving non-invasive mechanical ventilation (OR=0.099, 95% CI 0.028-0.354, \( p<0.001 \)). No fatal bleedings were observed.

Conclusion Treatment with therapeutic doses of T-LMWH is safe and seems to reduce mortality in COVID-19 patients with pneumonia, especially among those who need non-invasive mechanical ventilation. We look forward to prospective studies to confirm this observation and evaluate the appropriate dose of LMWH in the treatment of COVID-19 patients.

Introduction

The coronavirus SARS-CoV-2 infected thousands of people in Wuhan in December 2019 and spread rapidly worldwide. Since February 29, 2020, Castel San Giovanni Hospital in Italy was entirely dedicated to the treatment of coronavirus disease 2019 (COVID-19) patients. Pneumonia is the main clinical feature of COVID-19, however we observed several patients dying with very high D-dimer serum levels, suggesting a hypercoagulability state, as recently reported [1-3].

The relationship between inflammation and thrombosis is well recognized and the anticoagulant and anti-inflammatory activity of heparin may exert a beneficial effect on COVID-19 disease [4-5]. No specific pharmacological protocols with proved efficacy were, and actually are, available for treatment of Coronavirus disease [6]. We therefore hypothesized that treatment with Low Molecular Weight Heparin (LMWH) at a therapeutic dose could benefit COVID-19 patients and we decided, with clinical equipoise, to treat patients with therapeutic doses of LMWH taking advantage of its anticoagulant, anti-inflammatory, and in vitro antiviral properties [7-10].
The aim of this study is to evaluate the hospital mortality of COVID-19 patients treated with LMWH, administered at prophylactic doses (P-LMWH) and therapeutic doses (T-LMWH).

**Methods**

Adult patients, consecutively admitted to the Castel San Giovanni Hospital, from February 29, to April 7, 2020 with confirmed COVID-19 pneumonia were included in the study. The diagnosis was consistent with the World Health Organization interim guidelines [11] and was confirmed by RNA detection of the SARS-CoV-2 from oropharyngeal and nasopharyngeal swab sample. In all patients Computed Tomography scan diagnosis of pulmonary pneumonia was performed.

We excluded patients on hemodialysis and patients with a hospital stay $\leq$ 7 days to exclude either mild forms of disease with an early discharge or more advanced forms of disease with early death or early transfer to another hospital for whom heparin treatment would not be appropriate [12-13].

The therapeutic approach included hydroxychloroquine, azithromycin, anti-viral therapy (lopinavir/ritonavir and/or darunavir/cobicistat), corticosteroid, tocilizumab (in selected patients) and LMWH. From 24 February 2020 to 15 March 2020, our patients received P-LMWH corresponding to 4000 IU once a day, as suggested by International guidelines for bedridden patients [14]. On 16 March 2020, during a medical staff briefing, we decided to treat our patients with T-LMWH corresponding to 70-100/kg IU twice a day. The approval of the Healthcare Directorate of Piacenza Local Health Authority was obtained. Patients with a HAS BLED score $\geq$ 3 were excluded from T-LMWH treatment [15].

**Data Collection**

Data were extracted from electronic medical records and included age, gender, clinical characteristics, in-hospital pharmacological treatments and type of high-flow oxygen needed. The comorbidities recorded were arterial hypertension, diabetes mellitus, cardiovascular diseases (defined as history of myocardial infarction, ischemic stroke, and peripheral atheromasia), atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease (Cockroft-Gault e-GFR< 60 ml/min/1.73m2) and the presence of active or previous cancer. Bleeding events also recorded and classified according to International Society of Thrombosis and Hemostasis (ISTH) definition of bleeding [16]. Patients were followed up until discharge, death or April 20, 2020, whichever came first.

**End points**

The primary endpoint of the study was hospital mortality and the secondary endpoint was safety.

**Statistical analysis**

The cohorts of patients treated with P-LMWH and T-LMWH were compared on continuous variables using the t-test and on categorical variables using the $\chi^2$-test. Crude odds ratios of hospital mortality T-LMWH were obtained using univariate logistic regression analysis. In order to control for the different
proportion of patients receiving concomitant treatments in the two groups, adjusted odds ratios were estimated using multivariable logistic regression. All statistical analyses were performed using IBM SPSS, version 25 [16].

Results

During the enrolment period, 351 patients were admitted to Castel San Giovanni COVID Hospital. Ninety-four patients were excluded from the analysis for the following reasons: 30 were discharged, 43 died and 17 were transferred to other care units (7 to Intensive Care Units outside our province) within 7 days. Three were not COVID-19 confirmed patients and 1 patient was in hemodialysis. The characteristics of the 257 patients included in the analyses are shown in Table 1.

One hundred-thirty-one (51%) received P-LMWH (4000 IU once a day at least 7 days) and 126 patients (49%) received T-LMWH (70-100/kg IU twice a day at least 7 days) treatment.

Two hundred-thirty-two patients (90.3%) received empiric antibiotic treatment (azithromycin 500 mg/day for at least 5 days), 237 patients (92.2%) received hydroxychloroquine (200 mg twice a day for at least 5 days), 146 patients (55.7%) received corticosteroids (methylprednisolone 1 mg twice a day i.v. or dexamethasone 40 mg i.v. once a day for 3 days followed by decreasing dosage), 236 patients (91.8%) received anti-retroviral therapy (darunavir/cobicistat 800 + 150 mg, 1 tablet for 7 days and/or lopinavir/ritonavir 200 + 50 mg, 1 tablet twice a day for 7 days). Twenty-five patients (9.5%) were eligible for treatment with tocilizumab (8mg/kg i.v. in a single or double dose). D-dimer was collected in 93 patients and the mean peak level was 5241 µg/ml, the median level was 1489 µg/ml.

All patients required oxygen therapy: 135 patients (52.5%) needed nasal cannula with oxygen flow ≤ 6 l/min or non-rebreather mask with oxygen flow from 10 to 15 l/min (Vent 1); 67 patients (26.1%) required non-invasive mechanical ventilation (Vent 2) and 55 patients (21.4%) required invasive mechanical ventilation (Vent 3).

Patients treated with P-LMWH and T-LMWH had similar demographic and clinical characteristics (Table 1). However, patients in the T-LMWH group received more frequently corticosteroids, hydroxychloroquine and tocilizumab.

Hospital mortality in patients treated with T-LMWH vs. P-LMWH

During hospitalization 49 patients died (49/257, 19.1%). Hospital mortality was significantly lower in patients treated with T-LMWH (17/126, 13.5%) than in those treated with P-LMWH (32/131, 24.4%; $\chi^2=4.98$, p = 0.02). The crude odds ratio of mortality in patients treated with T-LMWH was OR=0.483, 95% CI 0.252-0.923, p<0.05.

When analyses were stratified by type of ventilation, patients with non-invasive mechanical ventilation (Vent-2) were those who mostly benefited from higher doses of heparin, since in these patients the mortality was lower than in those treated with P-LMWH (OR=0.099, 95% CI 0.028-0.354, p<0.001). In the other
two types of ventilation, no significant differences in mortality rates were observed (Vent1: OR=0.853, 95% CI 0.309-2.355, p=0.759; Vent 3: OR=0.792, 95% CI 0.220-2.852, p=0.721. Multivariate linear regression was conducted to determine whether T-LMWH was more effective than P-LMWH in reducing hospital mortality after controlling for concomitant administration of corticosteroids, hydroxychloroquine and tocilizumab. The results indicate a significant 62.6% reduction in the mortality risk among those treated with T-LMWH (OR=0.374, 95% CI 0.177-0.792, p=0.01) (Table 2).

**Safety of T-LMWH**

Two major and 1 minor bleeding episodes were recorded in group T-LMWH patients (3/126; 2.4 %): two patients had psoas muscle hematoma that required two packed red blood cells transfusion each and one patient had gluteus muscle hematoma that recovered spontaneously. No patient needed invasive treatment.

**Discussion**

In this retrospective study, T-LMWH appeared to be the only treatment associated with a significant reduction of mortality, after controlling for the concomitant in-hospital treatment.

Very few data exist on the relationship between therapeutic doses of LMWH and the reduction of mortality rate in COVID-19 patients. In a recent retrospective study, Tang et al. treated COVID-19 patients with therapeutic doses of heparin, reporting a low mortality rate at 28 days’ follow-up only in a subgroup of patients with SIC score ≥ 4 and D-dimer > 6-fold the upper limit [13]. During the first two weeks of our involvement in this emergency setting, D-dimer was not systematically recorded in all patients and no analysis could be carried out comparing this predictive parameter apart from few patients. In our study, patients who mostly benefited from therapeutic doses of heparin were those included in the Vent-2 group, who needed non-invasive mechanical ventilation with helmet CPAP (p<0.001).

We can speculate that in this specific clinical setting, the hypercoagulability state, which worsens the respiratory clinical picture, can benefit from the administration of therapeutic doses of heparin.

Conversely, in the mechanical ventilated patients’ group (Vent-3), a prognostic advantage from heparin at therapeutic doses was not found, probably because in Intensive Care Unit (ICU) patients the disease is too advanced to benefit from the anti-inflammatory and anticoagulant activity of heparin. Our findings are consistent with a recent retrospective analysis of 150 COVID-19 ICU patients, in which a significantly high thromboembolic event rate was found also in those treated with anticoagulant therapy [18]. Probably in such an advanced state of the disease even a therapeutic dose of heparin may not improve the outcome [19].

SARS-Cov-2 infection induces diffuse endothelial inflammatory status due to direct viral infection of the endothelial cells in different organs of the human body [20]. Endothelial damage is the main determinant of microvascular dysfunction that led to vasoconstriction and subsequent organ ischemia, inflammation,
tissue edema and a pro-coagulant state [21]. Hypercoagulability state has been demonstrated in other viral infections [22, 23]. During the epidemic SARS-CoV-2, vascular endothelial damage, in both small and mid-sized pulmonary vessels, was observed and resulted in pulmonary infarction [24, 25]. In COVID-19 patients, the radiological features observed on CT angiography images suggest venous and arterial thrombosis [26] and also in autopsy studies, diffuse thrombosis of the peripheral small vessels has been found [27, 28]. Therefore, the protective effect of T-LMWH is probably due to the prevention/treatment of such thrombotic events, which is in keeping with the benefit of anticoagulation in a particular subset of patients with severe pulmonary involvement.

Apart from its anticoagulant properties, LMWH has an anti-inflammatory effect that reduces the uncontrolled activation of the cytokine cascade by inhibiting the release of IL-6 [29]. High serum IL-6 levels are observed in the advanced stages of COVID-19, significantly and directly correlate with the severity of the disease [30,31,32].

Lastly, no fatal bleeding occurred in the study population and only 2 out of 126 patients (1.6 %) had bleeding requiring transfusions, which indicates that this treatment is safe [33].

Limitations in current retrospective observational study include the potential selection bias and residual confounding associated with a small sample size. It is also possible that the improving learning curve may have produced a non-pharmacological benefit in the management of patients over time. However our observation maybe useful to stimulate prospective studies to evaluate which heparin dose could be optimal in the treatment of Covid-19 patients.

**Conclusion**

In this retrospective study T-LMWH treatment reduces in-hospital mortality in COVID-19 patients and seems to be safe and well-tolerated. Future randomized clinical trials are still needed to confirm this observation.

**Declarations**

**Funding** No specific funding has supported this study.

**Ethics approval** The Healthcare Directorate of Piacenza Local Health Authority approved the therapeutic protocol.

**Consent to participate** The Healthcare Directorate of Piacenza Local Health Authority granted a waiver of informed consent.

**Consent for publication** No consent for publication was requested, because data are presented in aggregate form and do not include sensitive data.

**Availability of data and material** Data are available upon request from the first author.
**Code availability** A commercial software, IBM SPSS version 25.0, was used for the data analysis.

**Authors' contributions** Marco Stabile, Daniela Aschieri contributed to the design and implementation of the research, Enrico Fabrizi and Paola Rucci to the statistical analysis of the results. Marco Stabile, Daniela Aschieri, Cristina Maestri, Luca Rosato, Paola Novara and Gianluca Lanati contributed to the writing of the first draft of manuscript. Gloria Taliani contributed to the writing and the interpretation of the results. All authors provided important intellectual contents and approved the final version of the manuscript and agreed to the publication of the manuscript. Special thanks to the members of the COVID-19 Castel San Giovanni Group: Francesco Andrani, Angelo Benedetti, Mara Bozzarelli, Carlo Cagnoni, Paolo Cambrini, Esther Centenara, Sara Chiesa, Mauro Codeluppi, Patrizia Colazzo, Donatella Covini, Alessandro Esposito, Angelo Mangia, Demostene Marifoglou, Massimiliano Mazzilli, Samantha Mazzocchi, Monica Pellegrini, Iacopo Pellegrino, Annamaria Pieri, Daria Sacchini, Tiziana Spezzano, Corrado Tosca, Lucia Torretta, Gioacchino Valenti, Ercole Zanotti.

**References**

1. Chen N, Zhou M, Dong X et al. (2020) Epidemiological and clinical characteristics of cases of 2019 novel coronavirus pneumonia in Wuhan: a descriptive study. Lancet 395:207-513. 2. Huag C, Wang Y, Li X et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506. 3. Tang N, Li D, Wang X, Sun Z. (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. ;18(4):844-847. https://doi.org/10.1111/jth.14768. 4. Hao C, Sun M, Wang H, Zhang L et al. (2019) Low Molecular Weight Heparins and Their Clinic- al Applications. Prog Mol Biol Transl Sci163:21-39. 5. Hirsh J, Warkentin TE, Shaughnessy SG, et al. (2001) Heparin and low molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 119 (1 Suppl): 64S- 95S 6. Kalil AC (2020) Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA;323(19):1897–1898. doi:10.1001/jama.2020.4742 7. Mousavi S, Moradi M, Khorshidahmad T et al. (2015) Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv Pharmacol Sci:507151. doi:10.1155/2015/507151 8. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a re-view of immune changes in patients with viral pneumonia. Emerg Microbes Infec 2020; 9: 727- 732. 9. Johnson Z, Kosco-Vilbois MH, Heren S et al. (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Im- munol 173: 5776–5785 10. Thachil J. The versatile heparin in COVID-19. J. Thromb Haemost. https://doi.org/10.1111/jth.14821 11. Yang Y, Yang M, Shen C et al. (2020) Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019- nCoV infections. medRxiv. 2020 feb 17;2020.2.11.20021493. 12. Turpie AGG, Chin BSP, Lip GYH. (2002) Venous thromboembolism: treatment strategies. BMJ 26; 325: 948–950 13. Tang N, Bay H, Chen X et al. (2020) Anticoagulant treatment is associated with decreased mortal- ity in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094- 1099. doi: 10.1111/jth.14817 14. Holger J. Schünemann, Mary Cushman, Allison E. Burnett American Society of Hematology (2018) guidelines for management of venous thromboembolism:
prophylaxis for hospitalized and nonhospitalized medical patients Blood Adv. Nov 27; 2(22): 3198–3225.

15. Lip GYH, Frison L, Halperin JL et al. (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hyper-tension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57:173– 80 16. IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp. 17. Kaatz S, Ahmad D, Spyropoulos AC et al. (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119-21 18. Helms J, Tacquard C, Severac F et al. (2020) High risk of thrombosis in patients in severe SARS- CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 10.1007/s00134- 020-06062-x 19. Llitjos JF, Leclerc M, Chochois C et al. (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Intensive Care Med https://doi.org/10.1007/s00134- 020-06082-7 20. Varga Z, Flammer AJ, Steiger P et al. (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234): 1417–1418 21. Bonetti PO, Lerman LO, Lerman A. (2003) Endothelial dysfunction - a marker of atherosclerotic risk. Arterioscl Thromb Vasc 23:168–75 22. Antoniak S. (2018) The coagulation system in host defense. Res Pract Thromb Haemost 2(3):549– 57 23. Antoniak S, Mackman N. (2014) Multiple roles of the coagulation protease cascade during virus infection. Blood123(17):2605–13 24. Hwang, D, Chamberlain D, Poutanen S et al. (2005) Pulmonary pathology of severe acute respira- tory syndrome in Toronto. Mod Pathol 18, 1–10 . https://doi.org/10.1038/modpathol.3800247 25. Lax SF, Skok K, Zechn er P, et al. (2020) Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series [published online ahead of print, 2020 May 14]. Ann Intern Med. 2020;M20-2566. doi:10.7326/M20-2566 26. Casey K, Iteen A, Nicolini R et al. (2020) COVID-19 pneumonia with hemoptysis: Acute seg- mental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med S0735- 6757(20)30239-4. doi:10.1016/j.ajem.2020.04.011 27. Luo W, Yu H, Gou J et al. (2020) Clinical Pathology of Critical Patient with Novel Coronavirus Pneumonia (COVID-19). Preprints, 2020020407 28. Wichmann D, Sperhake J, Lutgehetmann M et al. (2020) Autopsy Findings and Venous Throm- boembolism in patients with COVID-19: A Prospective Cohort Study. Ann Intern Med doi:10.7326/M20-2003 29. Shastri MD, Stewart N, Horne J et al. (2015) In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparin. PLoS One. 11;10(5):e0126763. doi: 10.1371/journal.pone.0126763. 30. Pons S, Fodil S, Azoulay E, Zafrani L. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24(1):353. Published 2020 Jun 16. doi:10.1186/s13054-020-03062-7 31. Guang Chen, Di Wu, Wei Guo et al. (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J.Clin. Invest 130(5):2620-2629 32. Xu X, Han M, Li T, Sun W et al. (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. Apr 29. doi: 10.1073/pnas.2005615117 33. Cossette B, Pelletier ME, Carrier N et al. (2010) Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. Ann Pharmacother 44(6):994-1002. doi: 10.1345/aph.1M615
### Table 1. Demographic, clinical characteristics and treatment of the study population and comparisons between patients treated with P-LMWH (N=131) and T-LMWH (N=126).

| Variables                                      | Overall sample | P-LMWH | T-LMWH | p-value |
|------------------------------------------------|----------------|--------|--------|---------|
| Age (years)                                    | 69.3 ± 10.7    | 69.4 (11.9) | 69.2 (9.5) | 0.836°  |
| Gender                                         |                |        |        | 0.583^  |
| Male                                           | 174 (67.7%)    | 91 (69.5%) | 83 (65.9%) |         |
| Female                                         | 83 (32.3%)     | 40 (30.5%) | 43 (34.1%) |         |
| Arterial hypertension                          | 162 (63.0%)    | 83 (63.4%) | 79 (62.7%) | 0.913^  |
| Diabetes mellitus type 2                       | 46 (17.9%)     | 25 (19.1%) | 21 (16.7%) | 0.613^  |
| Cardiovascular disease                         | 44 (17.1%)     | 28 (21.4%) | 16 (12.7%) | 0.065^  |
| Dyslipidaemia                                  | 37 (14.4%)     | 19 (15.0%) | 18 (14.3%) | 0.879^  |
| Obesity                                        | 25 (9.7%)      | 12 (9.2%)  | 13 (10.3%) | 0.754^  |
| Smoke                                          | 21 (8.2 %)     | 12 (9.4%)  | 9 (7.1%)   | 0.518^  |
| Chronic or paroxysmal atrial fibrillation      | 33 (12.8%)     | 17 (13.0%) | 16 (12.8%) | 0.966^  |
| Chronic obstructive pulmonary disease          | 22 (8.6%)      | 13 (9.9%)  | 9 (7.1%)   | 0.426^  |
| Chronic kidney disease                         | 22 (8.6%)      | 14 (10.8%) | 8 (6.3%)   | 0.207^  |
| History of cancer                              | 18 (7.0%)      | 11 (8.4%)  | 7 (5.6%)   | 0.372^  |
| **IN-HOSPITAL TREATMENT**                      |                |        |        |         |
| Azithromycin                                   | 232 (90.3%)    | 108 (82.4%) | 114 (90.5%) | 0.061^  |
| Hydroxychloroquine                             | 237 (92.2%)    | 114 (87.0%) | 123 (97.6%) | 0.002^  |
| Corticosteroid                                 | 146 (56.8%)    | 44 (33.6%)  | 102 (81.0%) | <0.001^ |
| **Anti-viral therapy**                         |                |        |        |         |
| Lopinavir/ritonavir and/or Darunavir/cobicistat | 236 (91.8%)    | 118 (90.1%) | 119 (94.4%) | 0.191^  |
| Tocilizumab                                    | 25 (9.7%)      | 2 (1.5%)   | 23 (18.3%) | <0.001^ |
| **Oxygen support**                             |                |        |        |         |
| Vent 1                                         | 135 (52.5%)    | 78 (59.5%) | 57 (42.5%)   |         |
| Vent 2                                         | 67 (26.1%)     | 28 (21.4%) | 39 (31.0%)   |         |
| Vent 3                                         | 55 (21.4%)     | 25 (19.1%) | 30 (23.8%)   |         |

P-LMWH = Low Molecular Weight Heparin at prophylactic doses 4000 IU once a day; T-LMWH = Low Molecular Weight Heparin at therapeutic doses 70-100 IU twice a day. Vent 1: nasal cannula with oxygen.
flow ≤ 6 l/min or non-rebreather mask with oxygen flow from 10 to 15 l/min; Vent 2: non-invasive mechanical ventilation; Vent 3: invasive mechanical ventilation. ^Chi-square test. °t-test.

Table 2. Odds ratio of mortality in patients treated with T-LMWH vs. P-LMWH, adjusted for concomitant drug intake. Results of multivariable logistic regression model.

|                                      | B     | S.E.  | p     | OR   | 95% C.I.for OR |
|--------------------------------------|-------|-------|-------|------|----------------|
|                                      |       |       |       |      | Lower | Upper |
| T- LMWH vs. P- LMWH                  | -0.983| 0.382 | 0.010 | 0.374| 0.177 | 0.792 |
| Corticosteroids                      | 0.763 | 0.375 | 0.042 | 2.145| 1.029 | 4.474 |
| Hydroxychloroquine                   | 0.074 | 0.603 | 0.902 | 1.077| 0.330 | 3.513 |
| Tocilizumab                          | -0.878| 0.780 | 0.260 | 0.416| 0.090 | 1.918 |
| Constant                             | -1.470| 0.574 | 0.010 | 0.230|       |       |